T. Andrew Crockett recently stepped down as the CEO of KalVista Pharmaceuticals, a biotech company, after leading it since 2016. His career in the pharmaceutical industry spans various roles including senior management positions in companies both in the U.S. and...
T. Andrew Crockett recently stepped down as the CEO of KalVista Pharmaceuticals, a biotech company, after leading it since 2016. His career in the pharmaceutical industry spans various roles including senior management positions in companies both in the U.S. and the U.K. Notably, Crockett's tenure at KalVista included significant achievements, highlighted by a total compensation that peaked at over $3.6 million in 2023. Though primarily compensated through cash bonuses rather than stock awards, he demonstrated a commitment to driving company performance, as evidenced by the performance-based compensation program in place. Interestingly, Crockett's wealth is closely tied to his equity ownership in KalVista, where he was an active shareholder with over 565,000 shares, valued around 3.1% of the company. His strategic decisions and leadership will be recognized as pivotal in South establishing the firm within the competitive biotech landscape. After a significant career, Crockett's resignation marks an end to an important chapter for both him and the company.